{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:49:36Z","timestamp":1783964976230,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Churchill Pharmaceuticals LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40262-017-0536-2","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T19:17:52Z","timestamp":1492629472000},"page":"803-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies"],"prefix":"10.1007","volume":"56","author":[{"given":"Ronald","family":"Goldwater","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"536_CR1","unstructured":"International Agency for Research on Cancer. GLOBOCAN cancer fact sheets: prostate cancer. 2016. \n                        http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx\n                        \n                    . Accessed 23 Sept 2016."},{"issue":"1","key":"536_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"536_CR3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.steroids.2014.12.021","volume":"95","author":"L Gomez","year":"2015","unstructured":"Gomez L, Kovac JR, Lamb DJ. CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids. 2015;95:80\u20137.","journal-title":"Steroids"},{"issue":"2","key":"536_CR4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/pcan.2015.42","volume":"19","author":"N Nussbaum","year":"2016","unstructured":"Nussbaum N, George DJ, Abernethy AP, et al. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016;19(2):111\u201321.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"536_CR5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ncpuro1237","volume":"5","author":"AH Reid","year":"2008","unstructured":"Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. 2008;5(11):610\u201320.","journal-title":"Nat Clin Pract Urol"},{"issue":"28","key":"536_CR6","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563\u201371.","journal-title":"J Clin Oncol"},{"key":"536_CR7","unstructured":"Janssen Biotech Inc. Zytiga\u00ae (abiraterone acetate) tablets. 2016. \n                        https:\/\/www.zytigahcp.com\/shared\/product\/zytiga\/zytiga-prescribing-information.pdf\n                        \n                    . Accessed 16 Sept 2016."},{"key":"536_CR8","unstructured":"European Medicines Agency. Assessment report for Zytiga (abiraterone). 2011. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002321\/WC500112860.pdf\n                        \n                    . Accessed 16 Sept 2016."},{"key":"536_CR9","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): application number: 202379Orig1s000. Zytiga. 2010. \n                        http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202379Orig1s000ClinPharmR.pdf\n                        \n                    . Accessed 16 Sept 2016."},{"issue":"6","key":"536_CR10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/00970002042006005","volume":"42","author":"MN Martinez","year":"2002","unstructured":"Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42(6):620\u201343.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"536_CR11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.clinthera.2014.10.018","volume":"37","author":"PJ Desjardins","year":"2015","unstructured":"Desjardins PJ, Olugemo K, Solorio D, Young CL. Pharmacokinetic properties and tolerability of low-dose SoluMatrix diclofenac. Clin Ther. 2015;37(2):448\u201361.","journal-title":"Clin Ther"},{"issue":"4","key":"536_CR12","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10067-015-3121-9","volume":"35","author":"A Hussaini","year":"2016","unstructured":"Hussaini A, Solorio D, Young C. Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. Clin Rheumatol. 2016;35(4):1099\u2013104.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"536_CR13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40265-015-0392-z","volume":"75","author":"R Altman","year":"2015","unstructured":"Altman R, Bosch B, Brune K, et al. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs. 2015;75(8):859\u201377.","journal-title":"Drugs"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0536-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T09:32:38Z","timestamp":1497519158000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0536-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0536-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]}}}